Livforsakringsbolaget Skandia Omsesidigt Trims Position in Eli Lilly and Company

Hedge fund reduces stake in pharmaceutical giant by 4.3% in Q3

Mar. 18, 2026 at 9:35am

Got story updates? Submit your updates here. ›

Livforsakringsbolaget Skandia Omsesidigt, a Swedish hedge fund, decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 4.3% in the third quarter of 2026, according to a recent SEC filing. The firm now owns 26,506 shares of the pharmaceutical company's stock, valued at $20,207,000.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative drugs across a range of therapeutic areas. Institutional investor activity in the stock, such as this hedge fund's position adjustment, can provide insights into market sentiment and expectations around the company's performance.

The details

In its 13F filing, Livforsakringsbolaget Skandia Omsesidigt reported selling 1,200 shares of Eli Lilly during the third quarter. The hedge fund's total position in Eli Lilly is now valued at $20.2 million, representing approximately 0.8% of its overall portfolio.

  • Livforsakringsbolaget Skandia Omsesidigt filed its 13F report for the third quarter of 2026.

The players

Livforsakringsbolaget Skandia Omsesidigt

A Swedish hedge fund that manages investments for its parent company, Skandia Försäkring.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana, known for developing innovative drugs across a range of therapeutic areas.

Got photos? Submit your photos here. ›

The takeaway

This filing provides a glimpse into the investment strategy of a major institutional investor, Livforsakringsbolaget Skandia Omsesidigt, and its view on the prospects of pharmaceutical giant Eli Lilly. The reduction in the hedge fund's position may signal a shift in market sentiment or expectations around Eli Lilly's future performance.